Abiraterone acetate improves fatigue in prostate cancer patients, says international clinical trial

Stockholm, Sweden: Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, according to results from a phase III clinical trial presented today.

Read the whole article on Physorg

More from Physorg